BUSINESSJun 8 · 08:44 UTCMARKETWATCHSteve Goldstein

Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial

Zealand Pharma's shares fell in Copenhagen after the company reported that 20% of users discontinued its weight-loss drug due to gastrointestinal issues.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

Zealand Pharmaorganizationweight-loss drugtopicgastrointestinal issuestopicCopenhagenplace

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJun 2 · 07:43 UTC
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
HEALTHMay 19 · 13:05 UTC
People who lost the most weight on Ozempic saw huge health benefits
HEALTHApr 28 · 17:23 UTC
Cancer Drug Developer Erasca Sinks by Record 55% After Patient Death
HEALTHApr 22 · 13:25 UTC
Restrictions on obesity drug coverage force patients to pivot
HEALTHMay 28 · 10:45 UTC
CVS Caremark will cover Lilly’s weight loss drug Zepbound again after patient backlash
BUSINESSMay 12 · 12:02 UTC
Hims & Hers plummets 15% after first-quarter loss, weak earnings guidance